We are live on ! Find out more
BVS icon

Bioventus

134 hedge funds and large institutions have $320M invested in Bioventus in 2025 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 65 increasing their positions, 27 reducing their positions, and 31 closing their positions.

New
Increased
Maintained
Reduced
Closed

592% more call options, than puts

Call options by funds: $595K | Put options by funds: $86K

141% more repeat investments, than reductions

Existing positions increased: 65 | Existing positions reduced: 27

1.61% more ownership

Funds ownership: 71.31%72.92% (+1.6%)

0% more funds holding in top 10

Funds holding in top 10: 33 (0)

7% less funds holding

Funds holding: 144134 (-10)

29% less capital invested

Capital invested by funds: $448M → $320M (-$128M)

29% less first-time investments, than exits

New positions opened: 22 | Existing positions closed: 31

Holders
134
Holders Change
-10
Holders Change %
-6.94%
% of All Funds
1.76%
Holding in Top 10
3
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.04%
New
22
Increased
65
Reduced
27
Closed
31
Calls
$595K
Puts
$86K
Net Calls
+$509K
Net Calls Change
+$50K

BVS Hedge Fund Activity: Q2 2025 in Review

134 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Bioventus (BVS) for Q2 2025, worth a combined $320M — down 29% from $448M a quarter earlier.

Sellers outnumbered buyers: 31 funds closed out of BVS and 22 opened new positions — a net loss of 9 holders — while 27 trimmed existing stakes and 65 added.

The largest buyer was Nantahala Capital Management, adding an estimated $8.19M. The largest seller was Driehaus Capital Management, exiting entirely with an estimated $13.2M sold.

  • 134 institutional investors held Bioventus (BVS) as of Q2 2025, down from 144 in Q1 2025.
  • Funds reported $320M of Bioventus stock for Q2 2025, down 29% quarter-over-quarter.
  • 22 funds opened new Bioventus positions in Q2 2025 and 31 closed out, a net change of -9 holders.
  • The largest Bioventus buyer in Q2 2025 was Nantahala Capital Management, an estimated $8.19M added.
  • The largest Bioventus seller in Q2 2025 was Driehaus Capital Management, an estimated $13.2M sold.

Based on aggregated 13F filings for Q2 2025.